FDCDDQ
CRDL

Federation des caisses Desjardins du Quebec’s Cardiol Therapeutics CRDL Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,800
Closed -$1.5K – 2418
2023
Q4 		$1.5K Hold
1,800
– – ﹤0.01% 2109
2023
Q3 		$1.59K Hold
1,800
– – ﹤0.01% 2100
2023
Q2 		$1.58K Hold
1,800
– – ﹤0.01% 2092
2023
Q1 		$878 Sell
1,800
-3,000
-63% -$1.77K ﹤0.01% 2168
2022
Q4 		$2.45K Hold
4,800
– – ﹤0.01% 2175
2022
Q3 		$4.87K Sell
4,800
-3,000
-38% -$3.66K ﹤0.01% 2079
2022
Q2 		$10.2K Hold
7,800
– – ﹤0.01% 1951
2022
Q1 		$12K Buy
7,800
+1,800
+30% +$2.97K ﹤0.01% 1970
2021
Q4 		$11K Hold
6,000
– – ﹤0.01% 2001
2021
Q3 		$24.5K Buy
+6,000
New +$21.7K ﹤0.01% 1790

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's CRDL Position: Q1 2024 in Review

Federation des caisses Desjardins du Quebec sold out of Cardiol Therapeutics (CRDL) in Q1 2024, closing a stake of 1,800 shares — an estimated $1.5K sold.

Federation des caisses Desjardins du Quebec first reported a position in CRDL in Q3 2021 and held it in 10 quarters. The position peaked at $24.5K in Q3 2021. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2024.

  • Federation des caisses Desjardins du Quebec reported no remaining Cardiol Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 1,800 Cardiol Therapeutics shares in Q1 2024, an estimated $1.5K.
  • Federation des caisses Desjardins du Quebec first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 10 quarters.
  • Federation des caisses Desjardins du Quebec's Cardiol Therapeutics position peaked at $24.5K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2024.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2024, filed 15 May 2024.